Slide 1: FY2026/3 Business Results
FY2026/3 Business Results Perseus Proteomics Inc. May 18, 2026 Takuya Yokokawa President & CEO 1
Slide 2: Corporate philosophy
Corporate philosophy We contribute to global healthcare through cutting-edge antibody technology.
Slide 3: Table of Contents
Table of Contents 01 Plans and Results for FY2026/3 02 FY2026/3 Business Results 03 FY2027/3 Business Plans 04 Future Goals and Plans Supp. About Perseus Proteomics 33
Slide 4: Plans and Results for FY2026/3
01 Plans and Results for FY2026/3 44
Slide 5: FY2026/3: Plans and Results
FY2026/3：Plans and Results Plans Results 1 Out-licensing Activities：PPMX-T003/PPMX-T002 • Each pipeline has not been derived and activities are continuing Clinical Development：Investigator-initiated • There were 2 enrolled cases, and 5 registered cases ２ clinical trial of PPMX-T003 in Aggressive NK
Slide 6: Status of Development Pipeline
Status of Development Pipeline （PPMX-T004 is in a non-clinical trial phase and is moving to the discovery pipeline） 1) Aggressive NK-cell leukemia 2) Radioisotope-labeled antibody 3) RI:90Y 4) RI:225Ac ＊ Physician-initiated clinical trials are being conducted with the support of the AMED Drug Discov
Slide 7: Status of Out-Licensing Activities
Status of Out-Licensing Activities Actions: ✓ In addition to the Company’s own approach, a new contract was signed this fiscal year with a global consultant to strengthen out-licensing activities. PPMX-T003: ✓ Repeated approaches were made toward licensing this product to pharmaceutical companies, b
Slide 8: PPMX-T003: Characteristics of the Antibody and Progress in Polycythemia Vera
PPMX-T003： Characteristics of the Antibody and Progress in the Polycythemia Vera Area Cellular Iron Uptake Blocking by antibody by Transferrin Characteristics of the Antibody 1.Binding of Holo-Transferrin ２.PPMX-T003の結合 2. Binding of PPMX-T003 Iron ions ⚫ A fully human antibody obtained using a phag
Slide 9: PPMX-T003: Progress Status in the Aggressive NK-Cell Leukemia Area
PPMX-T003：Progress Status in the Aggressive NK-Cell Leukemia Area Hokkaido Tohoku Overview of the Investigator-Initiated Clinical Trial University University Hospital Kyoto University Hospital ⚫ Study design: open-label, non-randomized, dose-escalation Hospital ⚫ Target disease: aggressive NK-cell l
Slide 10: Status of Drug Discovery Pipeline
Status of Drug Discovery Pipeline 1) Antibody-drug conjugate 2) Bispecific antibody 3) IgG antibody 10 10
Slide 11: PPMX-T004: Progress Status
PPMX-T004：Progress Status Features and Current Status Results of comparisons between different DAR* values of PPMX-T004b (DAR2, DAR4, DAR8) and competitor efficacy ⚫ An antibody-drug conjugate (ADC) targeting CDH3 ⚫ This drug is designed to bind strongly to CDH3 and then be efficiently internalized
Slide 12: Antibody research support service
Antibody research support service Revenue from antibody research support has increased for six consecutive fiscal periods. Launch of antibody screening and production services using a camelid antibody library. Services Characteristics of camelid single-domain antibodies ⚫ One-tenth the molecular wei
Slide 13: Antibody/Reagent Sales
Antibody/Reagent Sales Offering more than 90 products, including a full lineup of all 48 human nuclear receptor antibodies In the fiscal year ending March 2026, sales of three new research-use antibody products began Highly trusted by academic researchers, these products are New Product Lineup used
Slide 14: FY2026/3 Business Results
02 FY2026/3 Business Results 14 14
Slide 15: FY2026/3 business results: Profit & Loss highlights
FY2026/3 business results Profit & Loss highlights （Unit：million yen） FY2025/3 FY2026/3 Antibody research support service Results Results Antibody/Reagent Sales Sales 120 135 Gross profit 104 116 SG & A 930 861 PPMX-T003 ANKL：Clinical Trial R&D expenses 594 573 Core Technology Costs other 335 287 Op
Slide 16: FY2026/3 business results: Balance Sheet highlights
FY2026/3 business results Balance Sheet highlights （Unit：million yen） Assets Liabilities 2025/3/31 2026/3/31 2025/3/31 2026/3/31 Cash & deposits 1,667 1,515 Current liabilities 124 65 Total current assets 1,775 1,608 Non-current liabilities 261 340 Non-current assets 42 14 Total liabilities 386 405
Slide 17: Overview of the 29th Stock Acquisition Rights
Overview of the 29th Stock Acquisition Rights the 29th Stock Acquisition Rights Allotment date 2026/1/5 Allottee Macquarie Bank Limited Number of Potential 3,680,000 shares (24.95% of the total 14,749,500 issued shares as of Shares September 30, 2025) Issue Price Total amount: ¥2,980,800 (¥81 per st
Slide 18: FY2027/3 Business Plans
03 FY2027/3 Business Plans 18 18
Slide 19: FY2027/3: Plan
FY2027/3：Plan Out-licensing Activities: 1 PPMX-T003 / PPMX-T002: Continue out-licensing activities Clinical Development: ２ PPMX-T003: Complete the investigator-initiated clinical trial for aggressive NK-cell leukemia (March 2027). Conduct PMDA consultations Exploratory Research: ３ PPMX-T004: Complet
Slide 20: Future Goals and Plans
04 Future Goals and Plans 20 20
Slide 21: Business Development: Antibody Discovery Technologies and AI-Driven Drug Discovery
Business Development: Deepening Technology Through the Integration of Antibody Discovery Technologies and AI-Driven Drug Discovery Enhancement Through Wet-Lab Strategy Dry-Lab Approaches Emerging Technology Core Technologies Development ・De novo antibody generation ・Hybridoma ・Improvement of affinit
Slide 22: Business Development: Synergies Created by Three Business Portfolios
Business Development: Synergies Created by Three Business Portfolios Drug Discovery Research and development of groundbreaking antibody therapeutics using our proprietary platform technologies (Value Creation) Antibody Research Support Only One Absorbing cutting-edge needs and insights through techn
Slide 23: Supp. About Perseus Proteomics
Supp. About Perseus Proteomics Supp.-1 23
Slide 24: Company outline
Company outline Company name Perseus Proteomics Inc. (PPMX) Established February 2001 ●Antibody (Ab) drug discovery Business ●Ab research support ●Ab/reagent sales Securities code TSE 4882 HQ is in this building Office HQ/Laboratory:30-1 Nihonbashi-Hakozakicho, Chuo-ku, Tokyo, Japan Nagoya Laborator
Slide 25: Business model
Business model 1. Antibody (Ab) Drug discovery Technical seeds, collaborative research Information on • Analysis of disease • Ab engineering • New target • Production technology clinical needs R&D cost Academia Information on clinical needs • Opinions from clinicians • Unmet medical needs • Clinical
Slide 26: Business model
Business model 2. Support of Ab research Income Pharmaceutical company •Ab production •R&D support •Analysis of Academia sequencing 3. Sales of Abs/reagents Income Pharmaceutical company • Ab • Reagents Academia Supp.-4 26
Slide 27: Characteristics
Our technology to obtain Abs Hybridoma method Phage display method Single B cell screening method Immunization Single cell Antigen-antibody PBMC, screening Infect E.coli reaction cells originated Ab Myeloma from producing Mouse Rabbit Human spleen cell IgG IgG IgG Elution Cleaning Hybridoma Human si
Slide 28: Inquiry and disclaimer
[Inquiry] Email: ir@ppmx.com https://www.ppmx.com/en/ This presentation material is prepared only to provide information for reference on investment, not to promote investment. The final decision on investment shall be made on your own. This presentation material includes forecast or estimates for t